Prepared: March 5, 2012

University of California, San Francisco CURRICULUM VITAE Name:

Martin P. Powers

Position:

Assistant Professor of Clinical Pathology, Step 2 Pathology School of Medicine

Address:

Box 0506, 185 Berry Street, 1008 University of California, San Francisco San Francisco, CA 94143 Voice: 415 514-8980 Fax: 415 514-8193 email: [email protected]

EDUCATION 1993 - 1997

Case Western Reserve University Cleveland, OH, USA

B.A.

Summa Cum Laude, Biology and Psychology

1997 - 2004

University of Michigan Ann Arbor MI, USA

M.D.

1999 - 2002

University of California, Berkeley, CA, USA

M.A..

Molecular & Cell Biology

2004 - 2005

NYPH Weill Cornell

Intern

Pathology

2005 - 2008

The Methodist Hospital

Resident

Pathology

2006 - 2008

The Methodist Hospital

Chief Resident

Pathology

2008 - 2009

Baylor College of Medicine

Fellow

Molecular Genetic Pathology

LICENSES, CERTIFICATION 2008

Medical License, Michigan (active)

2008

Medical License, Texas (active)

2010

Medical License, California (active) A111689

2008

Board Certification, Anatomic and Clinical Pathology

2009

Board Certification, Molecular Genetic Pathology

1 of 10

Prepared: March 5, 2012

PRINCIPAL POSITIONS HELD 2009 - present University of California, San Francisco

Assistant Professor of Clinical Pathology

OTHER POSITIONS HELD CONCURRENTLY 2009 - present Clinical Laboratory Medicine (WOS)

Assitant Professor

2009 - present Molecular Diagnostics Laboratory

Co-Director

HONORS AND AWARDS 2006

Houston Society of Clinical Pathologists Resident Award

2006

First place junior member abstract, CAP 2006 Meeting, San Diego, CA

KEYWORDS/AREAS OF INTEREST Molecular pathology, molecular diagnostics, personalized medicine, cancer, hematopathology, mutation analysis, gene-expression, miRNA, genetics, epigenetics, FISH, RT-PCR, soft-tissue sarcoma, kidney, leukemia, lymphoma. PROFESSIONAL ACTIVITIES CLINICAL Co-Medical Director, Molecular Diagnostics Laboratory, UCSF: I direct the oncology based testing of this mixed molecular genetics and molecular oncology laboratory and will soon begin signing out molecular oncology cases, and cross coverage for molecular genetics cases when needed. Medical Director, Applied Genomics CLIA lab. SUMMARY OF CLINICAL ACTIVITIES Since joining the lab in August 2009, the laboratory is offering a KRAS mutation test, has improved the procedure for 1p19q FISH testing in glioma, each of which was improved under my direction, and is about to offer a new test for specimen identity testing, which i contributed to the test menu. I have also led the efforts to bring on EGFR and PTEN FISH testing. We have added in 2011, MGMT methylation testing, MYC, MYCN and Iso17q testing by FISH. PROFESSIONAL ORGANIZATIONS Memberships 2005 - present United States and Canadian Academy of Pathology 2005 - present College of American Pathologists, 2009, Fellow, College of American Pathologists,

2 of 10

Prepared: March 5, 2012

2005 - present American Society of Clinical Pathology, 2009, Fellow, American Society of Clinical Pathology 2005 - present American Society of Investigative Pathology 2005 - present Association for Molecular Pathology 2008 - present American Association for Cancer Research Service to Professional Organizations 2006 - 2008

College of American Pathologists Delegate, Residents' Forum

SERVICE TO PROFESSIONAL PUBLICATIONS 2006 - present Ad hoc referee for Archives of Pathology and Laboratory Medicine INVITED PRESENTATIONS NATIONAL 2009

United States and Canadian Academy of Pathology "An RT-PCR Assay from FFPE Tissue Identifies a New FUSDDIT3 Gene Fusion in Myxoid Liposarcoma"

Platform Presentation

REGIONAL AND OTHER INVITED PRESENTATIONS 2006

Residents' Day, Houston Society of Clinical Pathologists

2008

University of California, San Francisco, AP seminar

2009

Experimental Pathology Research Seminar, Texas Children's Hospital

2009

Qiagen Workshop at Clinical Virology Symposium, Daytona FL

2009

Qiagen Workshop at Texas Medical Center

2009

Qiagen Teleconference for employees

2009

AP Lecture series, The Methodist Hospital Houston TX "Molecular pathology of colorectal carcinoma"

2011

UCSF Current Issues in Pathology Course "Practical molecular testing in surgical pathology"

CONTINUING EDUCATION COURSES ATTENDED 2009

Association of Molecular Pathology meeting

2010

United States and Canadian Academy of Pathology meeting

2010

Current issues in anatomic pathology

2009

I also get CME from the Departments Mechanisms of Disease conference (19 hours this year), The NEJM online CME credits (15 hours this year), and The Journal of Molecular Diagnostics CME course (50 hours of either SAM or CME last year (2009). 3 of 10

Prepared: March 5, 2012

2010

Association for Molecular Pathology meeting

2011

United States and Canadian Academy of Pathology Meeting

UNIVERSITY AND PUBLIC SERVICE UNIVERSITY SERVICE UCSF CAMPUS-WIDE 2009 - present Molecular Diagnostics Oversight Committee

Member

2011 - present Breast SPORE internal advisory board

Member

DEPARTMENTAL SERVICE 2009 -

Pathology Resident Interviews, 22 in last three years

Interviewer

TEACHING AND MENTORING TEACHING FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS Qtr

Academic Yr 2010 2011

Course Number and Title Inflammation and Neoplasia

2010 2011

Hypersensitivity and Rejection

2011 2012

Immunity and Inflammation

2011 2012

Hypersensitivity and Rejection

2011 2012

M3: Classification of Neoplasms

Teaching Contribution 3 hours of laboratory supervision 3 hours of laboratory supervision 3 hours of laboratory supervision 3 hours of laboratory supervision 3 hours of small group supervision

Units

Class Size 20

20

20

20

20

INFORMAL TEACHING 2009 - present Informal lectures on Molecular testing in colorectal cancer, lymphoma, leukemia, and the roles of miRNAs in oncology with residents and fellows on service (every 2 months)

4 of 10

Prepared: March 5, 2012

2009 - present Signout with discussion with residents and fellows on molecular oncology service 2009 - 2009

"Molecular Pathology of colorectal carcinoma" for AP/CP residents, November 2009, 1 hour

2010 - 2010

"Molecular pathology board review" for AP/CP residents, March 2010, 2 hours

2010 - 2010

"Molecular Oncology" for CSU genetic counseling students, March 2010, 2 hours

TEACHING NARRATIVE For this year, I have taught 5 hours of lectures in molecular oncology and pathology for residents and fellows in pathology and for graduate students in the genetic counseling program shared between UCSF and CSU-Stanislaus. Also, I have been teaching the principles of molecular diagnosis, the technical basis of our tests, the clinical utility of our tests, and the clinical utility of other testing in molecular oncology to the residents and fellows rotating in the molecular diagnostics lab (Jessica van Ziffle, Wendy Yang, Ellen Krasik, and Jessica Finn and Arun Wiita). Christopher Liverman and Geoff Wool were the most recent residents who experienced a more streamlined and intense one month molecular diagnostics and cytogenetics rotation. In this rotation, I provide a series of informal didactics on the principles of molecular oncology, basic molecular methods in oncology diagnostics, and the molecular pathology of all major organ systems, (Brain, Endocrine, GI, GU, GYN, Skin, Breast, Blood, Lymphoid, Lung and Sarcoma). In the upcoming year (s), I anticipate more lectures for the residents and fellows in molecular oncology as I plan to expand my formal lecture series to include teaching of molecular oncology for brain tumors, leukemia, lymphoma, melanoma, GU tumors, breast tumors, GYN tumors, and head and neck/endocrine tumors. Also we anticipate having 6 residents from CP rotating with us over the course of the year, and will begin to offer a required molecular pathology rotation for the AP only residents in molecular oncology with an emphasis on the molecular diagnostics of tumors including FISH.

MENTORING POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED Dates

Name

Fellow

Faculty Role

2009 - 2010

Wendy Yang, MD

MGP Fellow

Clinical molecular oncology training

2009 present

Jessica van Ziffle, PhD

Clinical molecular oncology training

2010 present

Nikoletta Sidiropoulos , MD

ABMG Clinical molecular genetics fellow MGP Fellow

2009 - 2009

Jessica Finn, MD Ellen Krasik, MD, PhD Arun Wiita,

2010 - 2010 2010 - 2010

CP resident CP resident CP resident 5 of 10

Clinical molecular oncology training and career and research mentor Clinical molecular oncology rotation Clinical molecular oncology rotation Clinical molecular

Current Position Hematopathologist, Genoptix, Carlsbad, CA, USA Fellow, UCSF

Fellow, UCSF

Resident, UCSF Fellow, UCSF PDF, UCSF

Prepared: March 5, 2012

Dates 2010 - 2010 2010 - 2010

2010 - 2010

2011 - 2011 2011 - 2011

2011 - 2011 2011 - 2011

2011 - 2011 2011 - 2011 2011 - 2011

2011 - 2011 2011 - 2012

2011 - 2011 2011 - 2011

2011 - 2011 2012 - 2012

2012 - 2012

2012 - 2012

Name MD, PhD Geoff Wool, MD, PhD Mima Sharma, MD Theresa Hyun, MD, PhD Vijay George, MD Gregor Krings, MD, PhD Taylor Sittler, MD Tara Saunders, MD Mike Deftos, MD, PhD Iwei Yeh, MD, PhD Nancy Joseph, MD, PhD Mike Cascio Heather Pua, MD, PhD Jessica Davis, MD Benjamin Buelow, MD, PhD Sara Barcia, MD Mike Angelo, MD, PhD Mike Nystrom, MD Brent Mendez,

Fellow

Faculty Role oncology rotation Clinical molecular oncology rotation Clinical molecular oncology rotation

CP resident CP resident

Current Position Resident, UCSF Resident, UCSF

HP Fellow

Clinical molecular oncology rotation

Instructor, UCSF

CP resident

Clinical molecular oncology rotation AP molecular oncology elective

Resident, UCSF

Clinical molecular oncology rotation Clinical molecular oncology rotation

Resident, UCSF

Clinical molecular oncology rotation Clinical molecular oncology rotation Clinical molecular oncology rotation

Practicing Pathologist, Santa Clara CA PDF, MSKCC

Clinical molecular oncology rotation Clinical molecular oncology rotation

Resident, UCSF

Clinical molecular oncology rotation Clinical molecular oncology rotation

Resident, UCSF

Clinical molecular oncology rotation Clinical Molecular Oncology Rotation Clinical Molecular Rotation

Resident, UCSF

Clinical Molecular rotation

Fellow, UCSF

AP resident

CP resident CP resident

HP fellow DP fellow AP resident

AP/CP resident MGP fellow

AP/CP resident AP/CP resident

AP/CP resident CP resident

AP/CP resident

HP Fellow

6 of 10

Fellow, UCSF

Resident, UCSF

Resident, UCSF

Fellow, UCSF

Resident, UCSF

Resident, UCSF

Resident, UCSF

Prepared: March 5, 2012

Dates

Name

Fellow

Faculty Role

Current Position

MD

SUMMARY OF TEACHING AND MENTORING HOURS 2009 - 2010

120 total hours of teaching (including preparation) Formal class or course teaching hours: 20 hours Informal class or course teaching hours: 100 hours Mentoring hours: 0 hours

2010 - 2011

Total anticipated hours of teaching: 200 hours

2011 - 2012

Total anticipated hours of teaching: 200 hours

RESEARCH AND CREATIVE ACTIVITIES RESEARCH AWARDS PAST TMHRI Research Scholars Program (Co-investigator) TMHRI

07/01/2006 - 06/30/2007 $40,000 direct/yr1

Cytokine activity and myelodysplasia (PI: Jeff Chang, MD, PhD) Pathology Department Resident's Grant (PI)

$40,000 total 01/01/2008 - 06/30/2008

TMH Pathology Chair

$10,000 direct/yr1

microRNA profiling of human kidney tumors

$10,000 total

PEER REVIEWED PUBLICATIONS 1. Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L, Zu Y, Chang CC. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 131(12):1789-93, 2007 Dec. PubMed PMID: 18081437. 2. Ahmed A*, Powers MP*, Dunphie CH, Youker KA, Rice L, Ewton A, and Chang C-C. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathol Res Pract. 2009;205(9):634-8. Epub 2009 May. PubMed PMID: 19446406. 3. Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, Lopez-Terrada DH. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a 7 of 10

Prepared: March 5, 2012

newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol. 2010 Oct;23(10):1307-15. Epub 2010 Jun 25. PMID: 20581806. 4. Powers MP, Alvarez K, Kim HJ, Monzon FA. Molecular Classification of Adult Renal Epithelial Neoplasms Using MicroRNA Expression and Virtual Karyotyping. Diagn Mol Pathol. 2011 Jun;20(2):63-70. PubMed PMID: 21532496 Jimenez C, Powers M, Parsa AT, Glastonbury C, Hagenkord JM, Tihan T. Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma. J Neurooncol. 2011 May 1. [Epub ahead of print] PubMed PMID: 21533839 6. French D, Smith A, Powers MP, Wu AH. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. Clin Chim Acta. 2011 May 7. [Epub ahead of print] PubMed PMID: 21575616 7. Been L, Olar A, Powers MP, Lopez-Terrada D, Laucirica R. Myxoid liposarcoma: A case report of a sentinel metastasis to the parotid gland with molecular confirmation. Diagnostic Cytopathology, n/a. doi: 10.1002/dc.21553 Review Articles 1. Powers M, Zhang W, Lopez-Terrada D, Czerniak BA, Lazar AJ. The molecular pathology of sarcomas. Cancer Biomark. 2011;9(1-6):475-91. PubMed PMID: 22112491. Books and Chapters 1. Powers MP, Melanoma. Chapter 23 in Diagnostic Molecular Pathology in Practice, Editor: Iris Schrivjer. Springer, 2011 2. Powers MP, Grenert JP. Lynch Syndrome. Chapter 27 in Diagnostic Molecular Pathology in Practice, Editor: Iris Schrijver. Springer, 2011

ABSTRACTS

1. Powers MP, Rushton JR, Yao H, Barkoh BA, Jones D, Luthra R. MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia. Poster Presentation at 2010 USCAP meeting, Washington DC USA RESEARCH PROGRAM Significant Publications:

8 of 10

Prepared: March 5, 2012

Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L, Zu Y, Chang CC. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 131(12):1789-93, 2007 Dec. In this publication, I performed some the molecular biology tests and trained one of the undergraduates in performing such analysis. I collected clinical data (along with H. Nishino) and organized all the molecular and clinical data and analyzed the data and did the statistical analysis. I wrote the first draft of the paper, and then revised the paper with C-C. Chang. Additionally, I wrote the grant that was used to partially fund this project (TMHRI Research Scholars Program, PI: Jeff Chang, MD, PhD) Ahmed A*, Powers MP*, Dunphie CH, Youker KA, Rice L, Ewton A, and Chang C-C. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. (Pathol Res Pract. 2009;205(9):634-8. Epub 2009 May 14. *co-first authors). In this paper, I took the data collected by A. Ahmed and organized and analyzed it, did the statistical analysis, and wrote the first draft of the paper and revised the paper with C-C. Chang. Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, Lopez-Terrada DH. Detection of myxoid liposarcoma associated FUS/DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Accepted for Publication, Modern Pathology. In this publication, I designed the primers and performed much of the benchwork with Hernandez and Patel, and then I wrote the first draft of the manuscript and then revised it with Drs. Lazar and Lopez-Terrada. Powers MP, Alvarez K, Kim H, Monzon FA. Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Submitted, under review. In this publication I did all the RNA work from extraction to microarray to analysis. I also wrote the first draft of the paper and revised it with Dr. Federico Monzon. I also wrote a small grant application to our chairman, Dr. Michael Lieberman to get some money to fund this project. Current Research Interests and Program My research interests are in the application of both the classical and novel technologies and discoveries of molecular biology to the clinical laboratory with a focus on molecular oncology. I plan to expand the information we have gained in the kidney tumors, and use that information to develop newer focused miRNA tests to help in the diagnosis of kidney tumors, and to be used in clinical studies on the prognosis, progression, and response to targeted drug therapy in patients with kidney cancer. I am also going to expand the miRNA knowledge we have gained to more than the common and classic kidney tumors we originally studied. I am also going take the information published in the miRNA literature and try to develop other clinical testing procedures involving miRNA in other tumors when clinically suggested. miRNA based diagnostics have yet to reach the clinic, and I am going to make it part of my research effort to take the technologies and information generated by us and others into clinically useful tests. My other project has been involved in the development of a clinically validated RT-PCR test for the common gene fusions in myxoid liposarcoma; paper in press). In this study, I designed the primers and performed much of the PCR and analyzed all the data. This project is an example of what I plan to continue to do after I arrive at UCSF: new molecular test development. I plan to interact with clinicians in hematology, oncology, laboratory medicine, and pathology to identify which molecular tests are needed to best help treat, triage, or diagnose certain patients, and then work to bring those tests into the UCSF Medical Center. This will also be part of my research program to develop and utilize the newest and best molecular technologies in the development of such tests. I will use both the literature and the currently

9 of 10

Prepared: March 5, 2012

available methods to bring a new test in house; however, when I see an opportunity to develop a better method, or to incorporate a new technology that will increase the accuracy, turnaround time, workflow, or information generated from an assay, I plan on developing a new test based on that method and comparing its clinical and analytic validity against the standard methods, if available, in an effort to bring the best tests to our patients. I expect new tests, as they are developed, will be published in the molecular diagnostics literature, and when patient care or outcome is directly studied, in the appropriate clinical field's literature. Therefore, in the next two years and beyond, I plan to incorporate new methods, such as liquid bead arrays, array CGH and SNP arrays, miRNAs, focused gene expression arrays, DNA methylation studies, and novel sequencing technologies (as possible examples) into the clinical diagnostics laboratory. I also hope to integrate the single molecular tests that we are doing into larger profiles, to bring us closer to providing a personalized molecular profile of each patient's tumor.

10 of 10